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Abstract: Diabetic retinopathy (DR) is a major cause of blindness worldwide and is the number 
one cause of blindness in working-age individuals in developed countries. We review the cur-
rent literature and discuss the pathogenesis, modifying risk factors, genetics, and treatment of 
DR. Special focus is placed on the rationale and effectiveness of therapeutic modalities, both 
current and future.
Introduction
Diabetes mellitus (DM) is a major cause of morbidity and mortality worldwide, 
especially in developed nations. Worldwide 135 million suffer from DM and in the 
United States alone, roughly 18 million individuals are affected with DM, 4.1 million 
of whom have sight-threatening diabetic retinopathy (DR). Complications from DR 
account for the leading cause of vision loss in the US working population (Klein et al 
1984a; Klein et al 1984b).
Clinically, DR can be classiﬁ  ed as nonproliferative or proliferative diabetic retinop-
athy (NPDR and PDR, respectively). Signs of NPDR include retinal microaneursyms, 
intraretinal dot and blot hemorrhages (DB), hard exudates (HE), and cotton wool 
spots (CWS). Intraretinal microvascular abnormalities (IRMA) and venous beading 
(VB) may be seen in severe NPDR or preproliferative diabetic retinopathy (Chew and 
Ferris 2006). Signs of PDR include retinal and optic disc neovascularization, which 
may cause preretinal, subhyaloid, and vitreous hemorrhage (VH) and tractional retinal 
detachment (TRD).
DR accounts for the vast majority of diabetes-related vision impairment. 
Microvascular damage increases retinal vascular permeability and may lead to diabetic 
macular edema (DME). The increased permeability allows egress of ﬂ  uid and plasma 
components, leading to thickening of the macula and lipoprotein deposition. DME 
prevalence increases with the grade of retinopathy and is the most common cause of 
vision loss in NPDR (Chew and Ferris 2006). Capillary closure within the macula 
may lead to foveal avascular zone enlargement or macular ischemia. VH and/or RD 
may complicate PDR; the former is the most common cause of blindness in diabetics 
(Klein et al 1984a; Klein et al 1984b). With extensive ischemia, neovascularization 
may occur in the iris and occlude the angle leading to neovascular glaucoma, which 
has a high-risk of severe, irreversible vision loss.
Along with macular edema and ischemia, cell dysfunction and/or death may 
contribute to visual impairment in the setting of DM. This concept is supported by 
the ﬁ  nding that, in addition to greater severity of DR and increased ﬂ  uorescein leak-
age, decreased summed electroretinographic oscillatory potentials was found to be 
an independent predictor of progression to severe PDR (Bresnick and Palta 1987a, 
1987b). Moreover, increased apoptosis of cells in all layers of the retina has been 
observed in animal models of DR and in post-mortem analysis of retinas from diabetic Clinical Ophthalmology 2008:2(2) 426
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patients (Barber et al 1998). However, it is unclear whether 
this increased cell death directly causes retinal dysfunction 
or represents loss of hypo- or non-functional cells.
Pathogenesis
Hyperglycemia leads to microvascular retinal disease 
through various postulated mechanisms, including the 
polyol pathway (Robinson et al 1983), advanced glycation 
end products (AGE) pathway (Brownlee et al 1988), the 
renin-angiotensinogen pathway (Deinum et al 1990), the 
angiogenesis pathway (especially that associated with 
vascular endothelial growth factor or VEGF) (Ferrara 1995), 
and pathways associated with oxidative damage (Kunisaki 
et al 1995). The ﬁ  rst mechanism, the polyol pathway, is no 
longer considered an important target for the therapy of 
DR. Hyperglycemia leads to an increase in aldose reductase 
enzyme activity and increased sorbitol production causing 
lens and retinal toxicity by various mechanisms including 
osmotic effects, breakdown of the blood-retina barrier, and 
loss of pericytes ( Engerman and Kern 1984; Cheung et al 
2005). Aldose reductase inhibitors have shown promise 
in animal models of DR, but human studies have had 
limited success (Anonymous 1993b). The other pathogenic 
pathways hold more promise for future therapies and these 
are discussed later in this review.
Risk factors for the progression 
of diabetic retinopathy
Risk factor modiﬁ  cation is the single most important inter-
vention in decreasing the rate of development and progression 
of DR. Although the duration of diabetes is a signiﬁ  cant risk 
factor, hyperglycemia and hypertension are the most critical 
modiﬁ  able risk factors (Jain et al 2003). The Wisconsin Epi-
demiologic Study of Diabetic Retinopathy (WESDR) con-
ducted a cross sectional population survey and found a linear 
relationship of A1C level correlated with retinopathy ie,the 
lower the A1C level the lower the prevalence of retinopathy 
(Klein et al 1988). The Diabetic Control and Complications 
Trial (DCCT) showed that type I diabetics prospectively ran-
domized to intensive glycemic therapy to maintain HgA1C 
below 7% had a 76% reduction in development of diabetic 
retinopathy, 47% reduction in the incidence of severe NPDR 
or PDR, 23% decreased incidence of macular edema, 54% 
reduction in the rate of progression of pre-existing diabetic 
retinopathy, and a 56% decrease in the need for laser therapy 
(Anonymous 1993a). A long-term sustained beneﬁ  t of initial 
intensive glycemic control was demonstrated by the Epide-
miology of Diabetes Interventions and Complications Trial 
(EDIC), an extension of the DCCT with study length of over 
10 years (Anonymous 2000b).
The United Kingdom Prospective Diabetes Study (UKPDS) 
conﬁ  rmed a beneﬁ  t of intensive glycemic control in decreasing 
the risk of progression of diabetic retinopathy in older type II 
diabetics (Anonymous 1998). Subsequent analysis showed that 
among diabetics who also had hypertension, tighter blood pres-
sure control (150/85) was as important as glycemic control. 
Diabetic retinopathy progression and visual acuity decline were 
reduced by 34% and 47% respectively versus those in the con-
trol group (blood pressure 180/105) (Anonymous 1998b).
A number of reports have identiﬁ  ed elevated serum lipids 
as a risk factor for the progression of various features of DR. 
The WESDR and the ETDRS showed an association between 
elevated total serum lipid and cholesterol levels and increased 
hard exudates (Klein et al 1991; Chew et al 1996), a signiﬁ  -
cant risk factor for moderate vision loss. Subsequent analysis 
showed that the presence of severe hard exudates was the 
strongest predictive factor in the development of subretinal 
ﬁ  brosis, an adverse clinical ﬁ  nding, in patients with DME 
(Fong et al 1997). Elevated serum triglycerides were also 
found to be a risk factor for development of high-risk PDR 
(Davis et al 1998). In a cohort of type 1 diabetics, a positive 
correlation between DR progression and elevated serum tri-
glycerides and negative correlation with serum HDL levels 
was identiﬁ  ed (Lyons et al 2004). Higher serum cholesterol 
and triglyceride levels increased the risk for progression of 
retinopathy while total and LDL cholesterol were positively 
associated with more severe retinal HE (van Leiden et al 
2002). In a prospective, double-blind randomized control 
trial, reduction of total and LDL cholesterol with simvastatin 
was associated with a reduction in worsening of vision from 
in type 1 or 2 diabetics (Sen et al 2002).
Pregnancy has been linked to the more rapid progression 
of DR (Chew et al 1995). Either poorer or paradoxically 
tighter glycemic control during pregnancy may lead to more 
rapid progression of DR. Systemic changes (eg, hormonal 
and cardiovascular), may also account for this observation 
(Anonymous 2000a). Nevertheless, improved blood glucose 
control and more stringent DR screening criteria are recom-
mended for pregnant diabetics.
Microalbuminuria and proteinuria indicative of diabetic 
nephropathy have been identiﬁ  ed as risk factors for DR 
progression in some, but not all, studies. Importantly, this 
may not be a causal relationship, but rather two sequelae 
of generalized angiopathy caused by changes in enzymatic 
reduction of heparin sulfate proteoglycan side chains 
(Deckert et al 1989). Danaparoid sodium, a mixture of Clinical Ophthalmology 2008:2(2) 427
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sulfated glycosaminoglycans with mainly heparan sulfate, 
improved proteinuria in type 1 diabetics (Gambaro 1998), 
but did not improve proteinuria or retinopathy among type 
2 diabetics (van der Pijl et al 1999).
The incidence of cataract is higher among diabetics than the 
general population and cataract extraction may be required to 
improve visual function and/or to improve the view to the retina 
for diagnostic and therapeutic purposes. DR may limit the visual 
prognosis after cataract extraction, especially in the presence 
of severe NPDR or PDR (Chew et al 1999). While newer 
phacoemulsiﬁ  cation techniques are associated with a lower 
incidence of DR progression, post-operative macular edema 
may still limit visual outcomes after cataract surgery (Krepler 
et al 2002). An association was found between progression of 
NPDR and rapid pre-operative glycemic control, suggesting 
that cataract surgery should be delayed until prolonged 
glycemic control has been achieved (Suto et al 2006).
In the US, African American and Latino populations 
have an increased incidence and severity of DR that cannot 
be explained by glycemic control alone. The great variability 
in severity of DR among populations with similar environ-
mental factors has fueled the search for genetics factors that 
may contribute to the development of DR (Uhlmann et al 
2006). Variations at several genetic loci have been implicated 
in DR, including VEGF, α2β1 integrin, ALR2 , angiotensin 
II receptor 1, RAGE, and PPARγ2 (Uhlmann et al 2006). 
However, the interpretation of the results of many of these 
studies is confounded by conﬂ  icting reports that have failed 
to conﬁ  rm such an association and the limited racial diversity 
of each of the study populations.
Conventional treatments
Traditional treatment of diabetic retinopathy has been shaped 
by the results of a few large prospective clinical trials. The 
Early Treatment Diabetic Retinopathy Study (ETDRS) 
sought to determine the efﬁ  cacy of photocoagulation in the 
treatment of diabetic macular edema (Anonymous 1991). 
Patients with mild, moderate, or severe NPDR or low-
risk PDR were randomized to immediate or delayed focal 
macular laser (FML) and immediate or delayed panretinal 
laser photocoagulation (PRP) for the treatment of clini-
cally signiﬁ  cant macular edema (CSME). Immediate FML 
decreased moderate vision loss by 50% in patients with 
CSME, while immediate PRP with delayed FML in patients 
with NPDR and CSME responded least favorably. The study 
group concluded that FML for CSME should be performed 
before scatter PRP in patients with NPDR. In patients with 
high-risk PDR and CSME, eyes should receive immediate 
PRP beginning nasally and inferiorly (to limit progression 
of macular edema) concurrently with FML.
The Diabetic Retinopathy Study (DRS) was designed to 
determine the efﬁ  cacy of PRP in preventing severe visual loss 
in eyes with advanced DR (Anonymous 1981). Study subjects 
with bilateral PDR or severe NPDR (ie, preproliferative 
DR) were given PRP in the ﬁ  rst eye and no treatment in the 
fellow eye. PRP reduced the risk of severe vision loss by 
50% or more in preproliferative and proliferative retinopathy 
(7% versus 3%). The effect was most marked in high risk 
PDR (26% versus 11%), as deﬁ  ned by the presence of any 
neovascularization of the disc (NVD) or retina with VH, or 
severe NVD with or without VH. The authors concluded that 
for severe NPDR, PDR, and especially high risk PDR, PRP 
is essential in preventing blindness. Side effects of treatment 
included peripheral visual ﬁ  eld constriction and nyctalopia. 
Additional complications of PRP include exacerbation of 
DME and contraction of retinal ﬁ  brosis, exacerbating TRD 
and/or causing retinal breaks.
The Diabetic Retinopathy Vitrectomy Study (DRVS) was 
designed to compare early versus delayed pars plana vitrec-
tomy (PPV) in patients with PDR, active neovascularization, 
and vitreous hemorrhage (Anonymous 1988). Patients with 
Type 1 DM, but not Type II DM, with dense non-clearing 
vitreous hemorrhage, had better outcomes with early vitrec-
tomy. The study group recommended early PPV for vitreous 
hemorrhage in the setting of Type 1 DM or for eyes with 
useful vision and advanced active PDR. An important caveat 
to this study is that endolaser (intraoperative PRP) was not 
used in this study, possibly limiting the applicability of the 
results to current clinical practice.
Although practice patterns vary widely, current indica-
tions for vitrectomy in the setting of DR include non-clearing 
VH, TRD threatening or involving the macula, or combined 
tractional and rhegmatogenous retinal detachment. A number 
of techniques may be employed for TRD repair, including 
the use of long-acting intraocular gas or silicone oil, that 
may improve anatomic and functional outcomes (Mason 
et al 2006). Vitrectomy has also been used in the treatment 
of recalcitrant DME, especially when a tractional component 
is present, although its beneﬁ  t has not been proven in a ran-
domized, controlled clinical trial (see below).
Treatments currently under clinical 
investigation
Despite these proven treatments for retinal complications 
of diabetes, patients with diabetic retinopathy continue to 
experience visual loss. A number of off-label non-FDA Clinical Ophthalmology 2008:2(2) 428
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approved treatment modalities are currently in clinical use 
and/or are under investigation for the treatment of various 
aspects of DR.
Corticosteroids
Periocular and intraocular triamcinolone acetonide (TA) 
have been used for the treatment of macular edema, 
including DME. This effect may be most pronounced in 
cases of cystoid macular edema (CME) or diffuse macular 
edema recalcitrant to laser therapy (Jonas et al 2001). 
A small randomized prospective clinical trial showed a 
beneﬁ  cial effect of intravitreal TA (Jonas et al 2006). 40 
eyes with diffuse DME were randomized to receive a single 
20 mg intravitreal TA or sham injection. At 3 and 6 months, 
81% and 87% of the eyes in the TA group had greater than a 
2 line improvement in visual acuity versus less than 30% in 
the control group. A beneﬁ  t was also seen in a randomized, 
controlled prospective trial of intravitreal TA for refractory 
DME with two-year follow-up (Gillies et al 2006). 69 
eyes were randomized to receive sham or intravitreal TA 
injections (4 mg), repeated up to ﬁ  ve times. Participants in 
both groups were eligible to receive focal photocoagulation 
if deemed necessary. At the end of the study, TA-treated 
eyes had a decreased mean retinal thickness and improved 
visual outcome, with a 5 line improvement in 56% or eyes, 
versus 26% in the placebo group.
A prospective trial comparing intravitreal TA to macular 
grid photocoagulation for the treatment of CME showed that 
TA was more effective than focal laser in this setting (Avita-
bile et al 2005). 48 patients with DME were randomized to 
receive photocoagulation, 4 mg TA, or both. The TA group 
had improved visual acuity and decreased retinal thickness 
when compared to the photocoagulation group. The group 
receiving both TA and photocoagulation was similar to TA 
alone. The Diabetic Retinopathy Clinical Research (DRCR) 
study group is currently evaluating TA versus photocoagula-
tion for the treatment of DME.
Triamcinolone has also been used as an adjunctive 
treatment to FML or PRP, to potentiate the effect of focal 
or panretinal photocoagulation or to minimize the develop-
ment or progression of macular edema (Kaderli et al 2005; 
Bandello et al 2006; Zein et al 2006; Choi et al 2007; Iida 
2007; Lam et al 2007). Despite the clear beneﬁ  ts of steroid 
therapy these must be judged against signiﬁ  cant side effects 
which include local problems such as redness, discomfort 
and ﬂ  oaters in the ﬁ  rst week after the injection and a high 
incidence of increased intraocular pressure and cataract. 
Blinding complications such as endophthalmitis, vitreous 
hemorrhage, or retinal vascular occlusion are fortunately 
very rare (Jonas et al 2006).
To circumvent the need for repeated injections, a number 
of sustained release devices are under investigation. A 
dexamethasone drug delivery system (Posurdex DDS, 
Dexamethasone Posterior Segment Drug Delivery System, 
Allergan) consists of a biodegradable copolymer of lactic 
acid and glycolic acid which releases dexamethasone for up 
to 6 months into the vitreous cavity. In a randomized control 
trial of the DDS for the treatment of persistent macular 
edema involving 315 patients with macular edema, 152 of 
whom had DME, use of a 700 implant μg was associated 
with a higher rate of 10 and 15-letter improvement in visual 
acuity, decreased ﬂ  uorescein leakage, and decreased retinal 
thickness (Kuppermann et al 2007). While there was an 
increased rate of IOP elevation in the treatment group, no 
eyes required glaucoma surgery or laser.
Other steroid delivery devices are being investigated for 
the treatment of ocular inﬂ  ammation, but may eventually ﬁ  nd 
use in the management of DME. Retisert (Control Delivery 
Systems and Bausch and Lomb) is an implantable nonbiode-
gradable intraocular device that delivers ﬂ  uocinolone aceton-
ide and is FDA approved for the treatment of noninfectious 
posterior uveitis (Jaffe et al 2006). Importantly, during the 
34-week trial, over 50% of patients required antihypertensive 
eyedrops and almost 6% required glaucoma ﬁ  ltering surgery 
and nearly 20% experienced signiﬁ  cant cataract progression, 
10% requiring cataract surgery. Thus, while such delivery 
devices may circumvent the need for repeated injections, 
they are still subject to signiﬁ  cant side effects.
The exact mechanisms by which steroids affects vascular 
permeability are not known. Downregulation of inﬂ  ammatory 
mediators and angiogenic cytokines has been demonstrated 
in various in vitro models (Antonetti et al 1998, 2002; 
Nauck et al 1998). However, a decrease in macular edema, 
as determined by OCT, was observed as soon as one hour 
after intravitreal injection of TA, arguing that nongenomic 
effects, such as direct restoration of the blood-retina bar-
rier or modulation of membrane channels, contribute to its 
salutary effects (Felinski and Antonetti 2005; Miyamoto 
et al 2006).
Vascular endothelial growth factor 
(VEGF)
VEGF has a central role in vascular permeability and 
angiogenesis in neovascular age-related macular degenera-
tion. VEGF has also been implicated in DR as an important 
angiogenic growth factor produced by areas of ischemic Clinical Ophthalmology 2008:2(2) 429
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retina. Vitreous levels of VEGF progressively increase with 
more advanced retinopathy and are greatest in eyes with PDR 
and least in eyes from non-diabetic individuals or diabetics 
without DR (Adamis et al 1994; Aiello et al 1994). A reduc-
tion of vitreous VEGF levels has been documented with PRP 
(Aiello et al 1994). VEGF levels have also been correlated 
with degree of macular edema, as determined by degree of 
leakage with ﬂ  uorescein angiography and central retinal 
thickness by OCT imaging (Funatsu et al 2006).
A prospective, double-masked clinical trial using 
pegaptanib sodium (Macugen, Eyetech), an aptamer that 
inhibits VEGF 165 isoform, for DME has been completed. 
(Cunningham et al 2005) One-hundred and seventy-two 
patients with DME and BCVA between 20/50 and 20/320 
were randomized to receive 0.3 mg, 1 mg, or 3 mg intravitreal 
pegaptanib injections or sham injections. Treatments were 
given at study entry, six weeks, and twelve weeks followed 
by additional injections with or without FML as needed for 
another 18 weeks. At the end of the 36-week trial, subjects 
in the 0.3 mg pegaptanib group had improved median BCVA 
(20/50 versus 20/63 in the sham group), and more eyes 
gained 10 letters (24% vs. 10%) and 15 letters (18% vs. 
7%). Mean central retinal thickness as determined by OCT 
decreased by 68 um, while it decreased by only 4 um in the 
control group. Photocoagulation was deemed necessary in 
25% of pegaptanib-treated eyes, while 48% of the control 
eyes received FML. No additional beneﬁ  t was seen with 
the higher doses of pegaptanib. The pegaptanib treatment 
was well tolerated, with only one case of culture-negative 
endophthalmitis reported.
Further analysis examined the effects of VEGF-inhibition 
on PDR. Sixteen eyes in this study group had proliferative 
diabetic retinopathy at study entry. Of the 13 eyes in the 
pegaptanib treatment arm, eight (62%) showed regression 
of neovascularization based on fundus photography or 
ﬂ  uorescein angiography. Of the 4 fellow eyes and 3 eyes 
from the control group with baseline neovascularization that 
were examined, none showed regression. Further evidence 
for a direct effect on proliferative changes from diabetic 
retinopathy was the progression in 3 of the eight eyes 
which had regressed on pegaptanib therapy at week 52 after 
discontinuing pegaptanib at week 30.
Ranibizumab (Lucentis, Genentech) is a neutralizing 
antibody targeted against all isoforms of VEGF which is 
FDA-approved for the intravitreal treatment of all subtypes 
of neovascular AMD. In a nonrandomized pilot study of 
ten patients, eyes with chronic DME received intraocular 
injections of 0.5 mg ranibizumab at study entry and at 
1, 2, 4, and 6 months (Chun et al 2006). At 7 months, mean 
visual acuity improved from 20/80 to 20/40 and mean foveal 
thickness decreased from 503 um to 246 um. No adverse 
events, including increase in foveal capillary nonperfusion, 
were reported.
Bevacizumab (Avastin, Genentech) is a humanized pan-
VEGF inhibiting antibody approved for colorectal cancer 
therapy. Whereas ranibizumab consists only of the Fc com-
ponent of the antibody, bevacizumab is the full antibody 
and is not FDA-approved for intraocular use. A prospective 
examination of 51 eyes with DME that received one or two 
injections of bevacizumab with 6 to 12 week follow-up has 
been reported (Haritoglou et al 2006). Mean retinal thickness 
decreased from 541 um to 417 um at 6 weeks and to 377 um 
at 12 weeks. However, a statistically-signiﬁ  cant improvement 
in visual acuity was only seen at the 6 week time point. Fur-
ther analysis showed that baseline visual acuity was the only 
predictive factor for an increase in visual acuity after 6 weeks 
of treatment. A more pronounced effect was reported in a 
retrospective analysis of 78 eyes with DME treated with 1 to 
3 intravitreal injections of bevacizumab (1.25 mg or 2.5 mg) 
(Arevalo et al 2007). Bevacizumab-treated eyes showed a 
decrease in mean retinal thickness, stabilization of visual 
acuity in 41% of eyes, and a 2 line improvement in 55% of 
patients after 6 months of follow-up.
Regression of iris, retinal and optic disc neovascular-
ization clinically and angiographically after intravitreal 
administration of bevacizumab has been shown in a large 
retrospective case series, although eventual reperfusion of the 
neovascular fronds was documented in several cases (Avery 
et al 2006). In some cases, the effects of VEGF-inhibition on 
PDR was seen as soon as 24 hours after treatment. Although 
not substantiated by randomized controlled trials, reduc-
tion in the caliber and fragility of neovascular lesions with 
anti-VEGF agents may decrease intraoperative hemorrhage 
during anterior and posterior segment surgery in the setting 
of PDR (Chen and Park 2006; Krzystolik et al 2006).
Other approaches to modulate intraocular VEGF activity 
are being investigated. Intraocular injection of a VEGF-
neutralizing anti-sense oligonucleotide has shown regression 
of ischemia-induced iris neovascularization in an animal 
model (Bhisitkul et al 2005). The VEGF trap (Regeneron, 
Bayer) is a soluble decoy VEGF receptor currently under 
investigation in the treatment of colorectal cancer (Konner 
and Dupont 2004). It consists of the binding domains of 
VEGF receptors 1 and 2, fused to the Fc fragment of IgG 
with a signiﬁ  cantly higher binding afﬁ  nity than monoclonal 
antibodies such as bevacizumab and ranibizumab for Clinical Ophthalmology 2008:2(2) 430
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VEGF-A. An exploratory study of the use of the VEGF trap 
in the treatment of ﬁ  ve patients with DME showed a decrease 
in retinal thickness and improvement in visual acuity, without 
serious adverse events (Do et al 2007).
Protein kinase C
Hyperglycemia is an important factor for the development 
and progression of diabetic retinopathy (Anonymous 1993, 
1998a). Hyperglycemia activates protein kinase C (PKC), 
a family of approximately 13 enzymes, through VEGF by 
inducing synthesis of diacylglycerol (Aiello 2002). In animal 
studies, upregulation of the beta-isoform increases retinal 
vascular permeability and neovascularization (Aiello et al 
1997; Xu et al 2004), while inhibition or genetic knockout 
reduces diabetes-induced retinal permeability and ischemia-
induced neovascularization (Danis et al 1998; Suzuma et al 
2002).
Ruboxistaurin mesylate (LY333531) is an oral PKC 
B-isozyme selective inhibitor that has been shown to 
ameliorate diabetic retinopathy in animal models and 
improve alterations in retinal blood flow from early 
diabetic retinopathy in human subjects. The Protein Kinase 
C Inhibitor Diabetic Retinopathy Study (PKC-DRS) was 
undertaken to determine whether ruboxistaurin reduces that 
rate of progression of nonproliferative diabetic retinopathy 
to proliferative retinopathy. (Aiello et al 2006) The results of 
the study did not support the primary hypothesis. However, 
when compared to the placebo group, the treatment group had 
a lower rate of moderate visual loss (5.5% vs. 9%), a greater 
likelihood to gain 15 letters from baseline and a reduction 
in the use of focal/grid photocoagulation by 26%.
Such ﬁ  ndings suggested that PKC B inhibition may 
decrease vascular permeability and DME. The Protein Kinase 
C Inhibitor Diabetic Macular Edema Study (PKC-DMES) 
was designed to determine the effect of orally-administered 
ruboxistaurin on DME (Anonymous 2007). In this phase 
III trial, 686 with DME that did not meet ETDRS-criteria 
for CSME were randomized to placebo or 4 mg, 16 mg, or 
32 mg/day of ruboxistaurin. After 30 months, there was 
no statistically signiﬁ  cant difference in the progression to 
sight-threatening DME or the need for focal/grid photoco-
agulation.
Octreotide
Several lines of evidence support a role for growth hormone 
in the progression of diabetic retinopathy (Wilkinson-Berka 
et al 2006). Two phase III studies of the insulin-like growth 
factor antagonist octreotide have been completed. In one 
study, monthly intramuscular injections of Sandostatin LAR 
reduced the progression of DR, but failed to beneﬁ  t visual 
acuity or macular edema. However, a second study of similar 
design failed to show a beneﬁ  cial effect on any of the outcome 
measures examined.
Vitrectomy
In addition to its role in the treatment of proliferative DR 
and vitreous hemorrhage, vitrectomy has been used for 
the treatment of DME (Lewis et al 1992). Spontaneous 
resolution of DME accompanying PVD has been reported. 
In one study, PVD was more prevalent in diabetics without 
DME than with DME (Nasrallah et al 1988; Nasrallah et al 
1989). Postulated mechanisms of action include relief of 
traction, removal of cytokines in the vitreous that promote 
vascular permeability and proliferation, and increasing 
oxygen diffusion to the retina. A retrospective analysis of 
65 eyes undergoing PPV with membrane peeling for DME 
showed a progressive decrease in mean retinal thickness 
and an improvement in visual acuity over the four month 
follow-up period (Yamamoto et al 2001).
Highly-puriﬁ  ed hyaluronidase (Vitrase, ISTA) has been 
studied in phase III clinical trials in the treatment of vitre-
ous hemorrhage (Kuppermann et al 2005). While it reduced 
vitreous hemorrhage and allowed photocoagulation, it did 
not show an improvement in visual acuity when compared to 
control. Intraocular Vitrase has been used to induce posterior 
vitreous detachment, but its role in the treatment of DME is 
yet to be elucidated.
Additional potential targets 
for future therapy
c-Raf kinase
The Ras/Raf/MAPK signaling pathway has been impli-
cated in angiogenesis in many types of systemic tumors 
and associated with ocular neovascularization. VEGF has 
been identiﬁ  ed as a downstream effector of this pathway. 
Intravitreal injection of an anti-raf-1-kinase antisense oligo-
nucleotide inhibited neovascularization in a porcine animal 
model (Danis et al 2003). 17-aminoallylgeldanamycin, an 
inhibitor of this pathway currently under investigation as a 
systemic chemotherapeutic, has been shown to inhibit retinal 
neovascularization in a mouse model of hypoxia-induced 
proliferative retinopathy. (Kociok et al 2007)
Erythropoietin
Erythropoeitin is another hypoxia-induced angiogenic factor 
that has been implicated in the pathogenesis of DR. Studies Clinical Ophthalmology 2008:2(2) 431
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have reported that vitreous levels of erythropoietin in eyes 
with PDR are signiﬁ  cantly higher than control (Katsura et al 
2005; Watanabe et al 2005). Aqueous levels of erythropoietin 
from eyes with DME were signiﬁ  cantly higher than those 
with neovascular AMD or control eyes.(Jonas and Neumaier 
2007) Another study found a stronger correlation between 
grade of PDR and erythropoietin than that with VEGF 
(Watanabe et al 2005).
Carbonic anyhdrase
Carbonic anhydrase I was recently identiﬁ  ed as one of 
117 proteins upregulated in vitreous samples of eyes with 
proliferative diabetic retinopathy using an unbiased, mass 
spectroscopy-based proteomic analysis (Gao et al 2007). 
In an animal model, carbonic anhydrase I increased retinal 
vascular leakage and retinal thickness through a kallikrein 
and bradykinin-dependent pathway. Acetazolamide, a car-
bonic anhydrase inhibitor, is widely used for treatment of 
glaucoma and cystoid macular edema in the setting of retinitis 
pigmentosa. Previously, in a small pilot case-control study 
of 12 diabetics, oral acetazolamide improved angiographic 
edema, but had an equivocal beneﬁ  t for visual acuity (Giusti 
et al 2001). Further study is needed to validate the biological 
and clinical importance of this pathway in DR and DME.
Benfotiamine
Benfotiamine, a thiamine derivative, inhibits three 
biochemical pathways of hyperglycemia-induced endothelial 
dysfunction, namely the hexosamine, AGE formation, 
and diacylglycerol-PKC pathways (Brownlee 2001). 
When administered to streptozocin-treated diabetic rats, 
benfotiamine decreased capillary changes from diabetic 
retinopathy (Hammes et al 2003). This treatment modality 
is currently under investigation for treatment of diabetic 
peripheral neuropathy (Haupt et al 2005) and holds promise 
in the prevention of DR.
Conclusions
DR remains a challenging clinical entity, both in terms of 
prevalence and morbidity. Laser photocoagulation remains 
the gold standard of care for vision-threatening complications 
of DR. Newer treatment modalities, especially triamcinolone 
and anti-VEGF therapy, are currently in widespread use, but 
there are no consensus guidelines regarding their use. Further 
understanding of the environmental, genetic, and biochemical 
factors that contribute to the development and progression 
of DR will continue to yield promising new targets for more 
effective and better-tolerated treatments. Despite current and 
future advances, prevention of DR by optimizing control of 
modiﬁ  able risk factors, especially glycemic and blood pres-
sure control, will undoubtedly continue to have the most 
important role in the control of this disease process.
Methods
A comprehensive literature search was performed using the 
PubMed database. Initial search terms included “diabetes,” 
“diabetic retinopathy,” and “macular edema.”
Support
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